Literature DB >> 24091833

Harnessing PD-L1-specific cytotoxic T cells for anti-leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway.

S M Ahmad1, S K Larsen1, I M Svane1, M H Andersen1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24091833     DOI： 10.1038/leu.2013.261

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cells.

Authors:  P Amé-Thomas; J Le Priol; H Yssel; G Caron; C Pangault; R Jean; N Martin; T Marafioti; P Gaulard; T Lamy; T Fest; G Semana; K Tarte
Journal:  Leukemia       Date:  2011-10-21       Impact factor: 11.528

2.  Evidence for involvement of clonally expanded CD8+ T cells in anticancer immune responses in CLL patients following nonmyeloablative conditioning and hematopoietic cell transplantation.

Authors:  T Kollgaard; S L Petersen; S Reker Hadrup; T N Masmas; T Seremet; M H Andersen; H O Madsen; L Vindeløv; P thor Straten
Journal:  Leukemia       Date:  2005-12       Impact factor: 11.528

3.  Cutaneous T cell lymphoma cells are targets for immune checkpoint ligand PD-L1-specific, cytotoxic T cells.

Authors:  S Munir; G H Andersen; A Woetmann; N Ødum; J C Becker; M H Andersen
Journal:  Leukemia       Date:  2013-04-18       Impact factor: 11.528

Review 4.  The blockade of immune checkpoints in cancer immunotherapy.

Authors:  Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

5.  Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma.

Authors:  H Tamura; M Ishibashi; T Yamashita; S Tanosaki; N Okuyama; A Kondo; H Hyodo; E Shinya; H Takahashi; H Dong; K Tamada; L Chen; K Dan; K Ogata
Journal:  Leukemia       Date:  2012-07-25       Impact factor: 11.528

Review 6.  Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.

Authors:  N W C J van de Donk; S Kamps; T Mutis; H M Lokhorst
Journal:  Leukemia       Date:  2011-08-19       Impact factor: 11.528

Review 7.  Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome.

Authors:  T Krejsgaard; N Odum; C Geisler; M A Wasik; A Woetmann
Journal:  Leukemia       Date:  2011-09-09       Impact factor: 11.528

8.  HLA-restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients.

Authors:  Shamaila Munir; Gitte Holmen Andersen; Özcan Met; Marco Donia; Thomas Mørch Frøsig; Stine Kiaer Larsen; Tobias Wirenfeldt Klausen; Inge Marie Svane; Mads Hald Andersen
Journal:  Cancer Res       Date:  2013-01-17       Impact factor: 12.701

9.  PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.

Authors:  Benjamin J Chen; Bjoern Chapuy; Jing Ouyang; Heather H Sun; Margaretha G M Roemer; Mina L Xu; Hongbo Yu; Christopher D M Fletcher; Gordon J Freeman; Margaret A Shipp; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2013-05-14       Impact factor: 12.531

10.  PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients.

Authors:  T Kozako; M Yoshimitsu; H Fujiwara; I Masamoto; S Horai; Y White; M Akimoto; S Suzuki; K Matsushita; K Uozumi; C Tei; N Arima
Journal:  Leukemia       Date:  2008-10-02       Impact factor: 11.528
View more
  23 in total

1.  Immune Regulation by Self-Recognition: Novel Possibilities for Anticancer Immunotherapy.

Authors:  Mads Hald Andersen
Journal:  J Natl Cancer Inst       Date:  2015-06-10       Impact factor: 13.506

Review 2.  Potential roles of self-reactive T cells in autoimmunity: lessons from cancer immunology.

Authors:  Mads Hald Andersen
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Hansen; Niels Junker; Troels Holz Borch; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2016-07-01       Impact factor: 8.110

4.  The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy.

Authors:  Shamaila Munir Ahmad; Evelina Martinenaite; Morten Holmström; Mia Aaboe Jørgensen; Özcan Met; Claudia Nastasi; Uffe Klausen; Marco Donia; Lars Møller Pedersen; Lars Munksgaard; Niels Ødum; Anders Woetmann; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-11-01       Impact factor: 8.110

5.  Indoleamine 2,3-dioxygenase vaccination.

Authors:  Mads Hald Andersen; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

Review 6.  Cancer immune therapy for myeloid malignancies: present and future.

Authors:  Morten Orebo Holmström; Hans Carl Hasselbalch
Journal:  Semin Immunopathol       Date:  2018-07-09       Impact factor: 9.623

7.  Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response.

Authors:  Morten Orebo Holmström; Caroline Hasselbalch Riley; Vibe Skov; Inge Marie Svane; Hans Carl Hasselbalch; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2018-02-27       Impact factor: 8.110

8.  Frequent adaptive immune responses against arginase-1.

Authors:  Evelina Martinenaite; Rasmus Erik Johansson Mortensen; Morten Hansen; Morten Orebo Holmström; Shamaila Munir Ahmad; Nicolai Grønne Dahlager Jørgensen; Özcan Met; Marco Donia; Inge Marie Svane; Mads Hald Andersen
Journal:  Oncoimmunology       Date:  2017-12-26       Impact factor: 8.110

9.  mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma.

Authors:  Troels Holz Borch; Lotte Engell-Noerregaard; Trine Zeeberg Iversen; Eva Ellebaek; Özcan Met; Morten Hansen; Mads Hald Andersen; Per Thor Straten; Inge Marie Svane
Journal:  Oncoimmunology       Date:  2016-07-08       Impact factor: 8.110

Review 10.  Anti-regulatory T cells.

Authors:  Mads Hald Andersen
Journal:  Semin Immunopathol       Date:  2016-09-27       Impact factor: 9.623
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.